Bruker Corporation Showcases New Microbial Diagnostics Solutions at ASM 2026
At ASM Microbe 2026, Bruker Corporation's Microbiology & Infection Diagnostics division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper CA System enabled by FDA Claims 7 and 8, supporting broader and more confident microbial identification in clinical laboratories. These enhancements include the MBT Compass HT CA software, MBT FAST Shuttle US IVD, and an expanded FDA-cleared reference library covering 549 clinically validated microbial species across bacteria, anaerobes, and yeasts. Bruker also highlights its focus on bloodstream infection and sepsis diagnostics, with a new vision to advance rapid antimicrobial susceptibility testing in clinical microbiology. Together with the MALDI Biotyper CA System and the Bruker Arc automated sample preparation solution for positive blood cultures, this innovative rapid AST workflow under development is expected to enable faster, actionable diagnostics to support earlier clinical decision-making in critically ill patients. Bruker also introduces multiple new solutions for the MALDI Biotyper RUO/GP systems to the U.S. market that were recently launched at ESCMID Global 2026, including the MBT Easy T Kit, MBT Compass HT RUO/GP v.500 with an expanded library covering 5,325 species, and the MBT HT Library Creator. The latest RUO/GP library expansion adds more than 600 new species, including ~30% improved coverage of filamentous fungi, addressing a challenge in microbiology. The MBT HT Library Creator Module lets laboratories generate, manage and share custom libraries within the MBT Compass HT environment, for research purposes. New classifiers for the IR Biotyper are also being introduced, further enhancing rapid outbreak investigation and surveillance capabilities.
